

DAFTAR PUSTAKA

1. World Health Organization. Global Status Report on Noncommunicable Diseases 2014. 2014; <https://apps.who.int/iris/handle/10665/148114>
2. World Health Organization (WHO). 2022. Diabetes Fact Sheets. Diunduh dari <https://www.who.int/news-room/fact-sheets/detail/diabetes> 30 Oktober 2022.
3. Edition S. IDF Diabetes Atlas, the Tenth Edition. 2021. 1–141 p. <https://diabetesatlas.org/atlas/tenth-edition/>
4. Khairani. Hari Diabetes Sedunia Tahun 2018. Pus Data dan Informasi Kementerian Kesehatan RI 2019: 1–8. <https://pusdatin.kemkes.go.id/article/view/19041500002/hari-diabetes-sedunia-2018.html>
5. Riset Kesehatan Dasar (RISKESDAS). Badan Penelitian dan Pengembangan Kesehatan Kementerian RI. 2018. Jakarta: Badan Litbang Kesehatan, 2018. https://kesmas.kemkes.go.id/assets/upload/dir_519d41d8cd98f00/files/Hasil-riskesdas-2018_1274.pdf
6. Kemenkes. Infodatin Tetap Produktif, Cegah, dan Atasi Diabetes Melitus 2020. Pusat Data dan Informasi Kementerian Kesehatan RI. 2020. P. 1–10. <https://www.kemkes.go.id/downloads/resources/download/pusdatin/infodatin/Infodatin%202020%20Diabetes%20Melitus.pdf>
7. Sarwar N, Gao P, Kondapally Seshasai SR, Gobin R, Kaptoge S, Di Angelantonio E, et al. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: A collaborative meta-analysis of 102 prospective studies. *Lancet*. 2010;375(9733):2215–22. [https://doi.org/10.1016/S0140-6736\(10\)60484-9](https://doi.org/10.1016/S0140-6736(10)60484-9)
8. Nogueira-Machado JA, Martins Chaves M. From hyperglycemia to AGE-RAGE interaction on the cell surface: A dangerous metabolic route for diabetic patients. *Expert Opin Ther Targets*. 2008;12(7):871–82. <https://doi.org/10.1517/14728222.12.7.871>
9. Volpe CMO, Villar-Delfino PH, Dos Anjos PMF, Nogueira-Machado JA. Cellular death, Reactive Oxygen Species (ROS) and Diabetic Complications Review-Article. *Cell Death Dis*. 2018;9(2). <https://rdcu.be/c6Mbl>
10. Peverill W, Powell LW, Skoien R. Evolving Concepts in The Pathogenesis of NASH: Beyond Steatosis and Inflammation. *Int J Mol Sci*. 2014;15(5):8591–638. <https://doi.org/10.3390/ijms15058591>
11. Mohamed J, Nazratun Nafizah AH, Zariyantey AH, Budin SB. Mechanisms of Diabetes-Induced Liver Damage: The Role of Oxidative Stress and

- Inflammation. Sultan Qaboos Univ Med J. 2016;16(2): e132–41. <https://doi.org/10.18295/squmj.2016.16.02.002>
12. Régnier M, Polizzi A, Smati S, Lukowicz C, Fougerat A, Lippi Y, et al. Hepatocyte-Specific Seletion of Ppara Promotes NAFLD in the Context of Obesity. *Sci Rep.* 2020;10(1):1–15. <https://doi.org/10.1038/s41598-020-63579-3>
 13. Kumar S, Shachi K, Dubey U. *Sci Forschen. J Diabetes Res Ther.* 2020; 2:9–11. <http://dx.doi.org/10.16966/2380-5544.150>
 14. Clifford T, Howatson G, West DJ, Stevenson EJ. The potential benefits of red beetroot supplementation in health and disease. *Nutrients.* 2015;7(4):2801–22. <https://doi.org/10.3390/nu7042801>
 15. Al-Harbi LN, Alshammari GM, Al-Dossari AM, Subash-Babu P, Binobead MA, Alhussain MH, et al. Beta vulgaris. L (beetroot) methanolic extract prevents hepatic steatosis and liver damage in t2dm rats by hypoglycemic, insulin-sensitizing, antioxidant effects, and upregulation of ppara. *Biology (Basel).* 2021;10(12). <https://doi.org/10.3390/biology10121306>
 16. Chhikara N, Kushwaha K, Jaglan S, Sharma P, Panghal A. Nutritional, Physicochemical, and Functional Quality of Beetroot (*Beta vulgaris* L.) incorporated Asian noodles. *Cereal Chem.* 2019;96(1):154–61. <https://doi.org/10.1016/j.foodchem.2018.08.022>
 17. Maliangkay, H. P., Rumondor, R., Mario Walean, dan, Studi Farmasi, P. & Tinggi Ilmu Kesehatan Trinita Manado, S. Uji Efektifitas Antidiabetes Ekstrak Etanol Kulit Buah Manggis (*Garcinia mangostana* L) Pada Tikus Putih (*Rattus norvegicus*) Yang Diinduksi Aloksan. *Chem. Prog* 11, 15 (2018). https://www.researchgate.net/publication/343253810_UJI_EFEKTIFITAS_A_NTIDIABETES_EKSTRAK_ETANOL_KULIT_BUAH_MANGGIS_Garcinia_mangostana_L_PADA_TIKUS_PUTIH_Rattus_norvegicus_YANG_DIINDUKSI_ALOKSAN
 18. Rompas, I. Z., Bodhi, W. & Lebang, J. S. Antihyperglycemic Effectiveness Test of Ethanol Extract of Red Gedi Leaves (*Abelmoschus manihot* L. Medik) Against White Rats (*Rattus Norvegicus*) Wistar Strain Induced By Alloxan Uji Efektivitas Antihyperglikemik Ekstrak Etanol Daun Gedi Merah (*Abelmoschus*. 10, 940–947 (2021). <https://ejournal.unsrat.ac.id/v3/index.php/pharmacon/article/view/35595/33318>
 19. Solis Herrera C, Triplitt C, Reasner C, et al. Classification of Diabetes Mellitus. [Updated 2018 Feb 24]. In: Feingold KR, Anawalt B, Boyce A, et

- al., editors. Endotext. South Dartmouth (MA): MDText.com, Inc.; 2000-.
<http://www.ncbi.nlm.nih.gov/books/nbk279115/>
20. Sapra A, Bhandari P. Diabetes Mellitus. [Updated 2021 Sep 18]. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2022
<https://www.ncbi.nlm.nih.gov/books/NBK551501/>
 21. Bellou V, Belbasis L, Tzoulaki I, Evarlou E. Risk Factors for Type 2 Diabetes Mellitus: An Exposure-Wide Umbrella Review of Meta-Analyses. *PloS ONE*. 2018; 13(3): 1-27. <https://doi.org/10.1371/journal.pone.0194127>
 22. Pangestika H, Ekawati D, Murni NS. Faktor-Faktor Yang Berhubungan Dengan Kejadian Diabetes Mellitus Tipe 2. *J 'Aisyiyah Med*. 2022;7(1):27–31. <http://dx.doi.org/10.36729/jam.v7i1.779>
 23. Banday MZ, Sameer AS, Nissar S. Pathophysiology of Diabetes: An overview. *Avicenna J Med*. 2020;10(04):174–88. https://doi.org/10.4103/ajm.ajm_53_20
 24. Johnson EL, Feldman H, Butts A, Chamberlain J, Collins B, Doyle-Delgado K, et al. Standards of Medical Care in Diabetes—2020 abridged for primary care providers. *Clin Diabetes*. 2020;38(1):10–38. <https://doi.org/10.2337/cd18-0105>
 25. Meneghini LF. Insulin Therapy for Type 2 Diabetes. *Endocrine*. 2013;43(3):529–34. <https://doi.org/10.1007/s12020-012-9817-6>
 26. Petznick A. Insulin Management of Type 2 Diabetes Mellitus. *Am Fam Physician*. 2011 Jul 15;84(2):183-90. PMID: 21766768. <https://www.aafp.org/pubs/afp/issues/2011/0715/p183.html>
 27. Ganesan K, Sultan S. Oral Hypoglycemic Medications. *StatPearls*. 2019 <https://www.statpearls.com/articlelibrary/viewarticle/26266/>
 28. Liu W, Baker RD, Bhatia T, Zhu L, Baker SS. Pathogenesis of Non-Alcoholic Steatohepatitis. *Cell Mol Life Sci*. 2016;73(10):1969–87. <https://doi.org/10.1007/s00018-016-2161-x>
 29. Postic C, Girard J. Contribution of De Novo Fatty Acid Synthesis to Hepatic Steatosis and Insulin Resistance: Lessons from genetically engineered mice. *J Clin Invest*. 2008;118(3):829–38. <https://doi.org/10.1172/JCI34275>
 30. Savage DB, Petersen KF, Shulman GI. Disordered Lipid Metabolism and The Pathogenesis of Insulin Resistance. *Physiol Rev*. 2007;87(2):507–20. <https://doi.org/10.1152/physrev.00024.2006>
 31. Gastaldelli A, Gaggini M, DeFronzo RA. Role of Adipose Tissue Insulin Resistance in The Natural History of Type 2 Diabetes: Results from the san antonio metabolism study. *Diabetes*. 2017;66(4):815–22.

<https://doi.org/10.2337/db16-1167>

32. Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: From Obesity to Metabolic Syndrome and Diabetes. *Diabetol Metab Syndr*. 2020;12(1):1–20. <https://doi.org/10.1186/s13098-020-00570-y>
33. Miele L, Valenza V, La Torre G, Montalto M, Cammarota G, Ricci R, et al. Increased Intestinal Permeability and Tight Junction Alterations in Nonalcoholic Fatty Liver Disease. *Hepatology*. 2009;49(6):1877–87. <https://doi.org/10.1002/hep.22848>
34. Kahn SE, Cooper ME, Del Prato S. *Pathophysiology and Treatment of Type 2 Diabetes: Perspectives On The Past, Present, And Future*. *Lancet* (London, England). 2014; 383: 1068–83. [https://doi.org/10.1016/s0140-6736\(13\)62154-6](https://doi.org/10.1016/s0140-6736(13)62154-6)
35. M.G. N, L.B. C, R.M. N. Biomarkers in Non-Alcoholic Fatty Liver Disease. *Can J Gastroenterol Hepatol*. 2014;28(11):607–18. <https://doi.org/10.1155/2014/757929>
36. Dufour DR, Lott JA, Nolte FS, Gretch DR, Koff RS, Seeff LB. Diagnosis and Monitoring of Hepatic Injury. I. Performance characteristics of laboratory tests. *Clin Chem*. 2000;46(12):2027–49. <https://doi.org/10.1093/clinchem/46.12.2050>
37. Moriles KE, Azer SA. Alanine Amino Transferase. *StatPearls*. 2020 <http://www.ncbi.nlm.nih.gov/books/nbk559278/>
38. Ro, E. V., Af, B. O., & Vi Ro, Y. E. (n.d.). *Safety Assessment of Transgenic Organisms OECD CONSENSUS DOCUMENTS BIOSAFETY EN Volume 1*. 2006. p. 174-196 https://read.oecd-ilibrary.org/science-and-technology/safety-assessment-of-transgenic-organisms_9789264095380-en#page7
39. Lange W, Brandenburg WA, De Bock TSM. Taxonomy and Cul-tonomy of Beet (*Beta vulgaris* L.). *Bot J Linn Soc*. 1999;130(1):81–96. <https://doi.org/10.1006/bojl.1998.0250>
40. Spiegel M, Gamian A, Sroka Z. Antiradical Activity of Beetroot (*Beta vulgaris* l.) betalains. *Molecules*. 2021;26(9):1–20. <https://doi.org/10.3390/molecules26092439>
41. Gezgin-Oktayoglu S, Sacan O, Bolkent S, Ipci Y, Kabasakal L, Sener G, et al. Chard (*Beta vulgaris* L. var. cicla) Extract Ameliorates Hyperglycemia by Increasing GLUT2 Through Akt2 and Antioxidant Defense in The Liver of Rats. *Acta Histochem*. 2014;116(1):32–9. <https://doi.org/10.1016/j.acthis.2013.04.016>

42. Neelwarne, Bhagyalakshmi. Red Beet Biotechnology: Food and Pharmaceutical Applications. 2012. 10.1007/978-1-4614-3458-0. https://doi.org/10.1007/978-1-4614-3458-0_1
43. Hashem AN, Soliman MS, Hamed MA, Swilam NF, Lindequist U, Nawwar MA. Beta Vulgaris Subspecies Cicla Var. Flavescens (Swiss chard): Flavonoids, Hepatoprotective and Hypolipidemic Activities. *Pharmazie*. 2016;71(4):227–32. <https://doi.org/10.1691/ph.2016.5821>
44. Liliana C, Oana-Viorela N. Red Beetroot: Composition and Health Effects – A Review. *J Nutr Med Diet Care*. 2020;5(2). <http://dx.doi.org/10.23937/2572-3278.1510043>
45. Neha P, Sk J, Nk J, Hk J, Hk M. Chemical and Functional Properties of Beetroot (Beta vulgaris L.) For Product Development: A review. . *Int J Chem Stud*. 2018;6(3):3190–4. <https://www.chemijournal.com/archives/2018/vol6issue3/PartAT/6-3-271-656.pdf>
46. Sasa S, Franc B, Matjaz T, Ana S, Crtomir R, Martina B. Nutritional Value and Economic Feasibility of Red Beetroot (Beta vulgaris L. ssp. Vulgaris Rote Kugel) from Different Production Systems. *African J Agric Res*. 2012;7(42):5653–60. <https://doi.org/10.5897/AJAR12.1519>
47. Babarykin D, Smirnova G, Pundinsh I, Vasiljeva S, Krumina G, Agejchenko V. Red Beet Impact on Human Health. *J Biosci Med*. 2019;07(03):61–79. <https://doi.org/10.4236/jbm.2019.73007>
48. Sakhare K, Sawate R, RB K, Taur A. Studies on Physical and Chemical Composition of Beetroot (Beta vulgaris L.). *Int J Chem Stud*. 2019;7(2):283–5. <https://www.chemijournal.com/archives/2019/vol7issue2/PartE/7-1-574-975.pdf>
49. Ananda, L. Karakteristik Fisikokimia Serbuk Bit Merah (Beta Vulgaris L.) Yang Diproses Dengan Variasi Drying Agents Dan Maltodekstrin Sebagai Coating Agent Physicochemical. (2008). <https://onsearch.id/Record/IOS2679.7004/TOC>
50. Miraj, S. Chemistry and pharmacological effect of beta vulgaris: A systematic review. *Der Pharm. Lett*. 8, 404–409 (2016). <https://core.ac.uk/download/pdf/143840588.pdf>
51. Manach C, Williamson G, Morand C, Scalbert A, Rémésy C. Bioavailability and Bioefficacy of Polyphenols in Humans. I. Review of 97 bioavailability studies. *Am J Clin Nutr*. 2005;81(1 Suppl):230–42. <https://doi.org/10.1093/ajcn/81.1.230s>

52. Zielinska-Przyjemska M, Olejnik A, Dobrowolska-Zachwieja A, Grajek W (2009) In vitro Effects of Beetroot Juice and Chips on Oxidative Metabolism and Apoptosis in Neutrophils From Obese Individuals. *Phytotherapy Research* 23: 49-55. <https://doi.org/10.1002/ptr.2535>
53. Akbari A, Jelodar G, Nazifi S, Sajedianfard J. An Overview of the Characteristics and Function of Vitamin C in Various Tissues: Relying on its Antioxidant Function. *Zahedan J Res Med Sci.* 2016;In Press(In Press). <https://dx.doi.org/10.17795/zjrms-4037>
54. Gupta P, Kour J, Bakshi M, Kalsi R. Flavonoids. *Nutraceuticals Heal Care.* 2021:105–13. <https://dx.doi.org/10.1016/b978-0-323-89779-2.00001-6>
55. Fuhrman B, Buch S, Vaya J, Belinky PA, Coleman R, Hayek T, et al. Licorice Extract and Its Major Polyphenol Glabridin Protect Low-Density Lipoprotein Against Lipid Peroxidation: In vitro and ex vivo studies in humans and in atherosclerotic apolipoprotein E-deficient mice. *Am J Clin Nutr.* 1997;66(2):267–75. <https://doi.org/10.1093/ajcn/66.2.267>
56. Zhu W, Jia Q, Wang Y, Zhang Y, Xia M. The anthocyanin cyanidin-3-O- β -glucoside, a flavonoid, increases hepatic glutathione synthesis and protects hepatocytes against reactive oxygen species during hyperglycemia: Involvement of a cAMP-PKA-dependent signaling pathway. *Free Radic Biol Med.* 2012;52(2):314–27. <https://doi.org/10.1016/j.freeradbiomed.2011.10.483>
57. Szabadfi, K., Pinter, E., Reglodi, D. & Gabriel, R. *Neuropeptides, trophic factors, and other substances providing morphofunctional and metabolic protection in experimental models of diabetic retinopathy. International Review of Cell and Molecular Biology.* 2014. 311. <https://doi.org/10.1016/b978-0-12-800179-0.00001-5>
58. Chougale, A. D., Panaskar, S., Gurao, P. & Arvindekar, A. U. Optimization of alloxan dose is essential to induce stable diabetes for prolonged period. *Asian Journal of Biochemistry* 2. 2007. P. 402–408 <https://dx.doi.org/10.3923/ajb.2007.402.408>
59. Rahman, S. S. *et al.* Evaluation and optimization of effective-dose of alloxan for inducing type-2 diabetes mellitus in long evans rat. *Indian J. Pharm. Educ.* 2017. Res. 51, S661–S666. <http://dx.doi.org/10.5530/ijper.51.4s.96>
60. Hasan, K. M. M., Tamanna, N. & Haque, M. A. Biochemical and histopathological profiling of Wistar rat treated with Brassica napus as a supplementary feed. *Food Sci. Hum. Wellness.* 2018. p. 7, 77–82. <https://doi.org/10.1016/j.fshw.2017.12.002>

61. Dahlan SM. Statistik Untuk Kedokteran dan Kesehatan. Salemba Medika. 2019. P. 27.
62. Hardimarta FP, Ikawati K, Yuniarti CA. Perbaikan Gambaran Lesi Aterosklerotik Dengan Pemberian Ekstrak Beta Vulgaris Pada Tikus Model Diet Atherogenik. *J Media Farm Indones.* 2020;15(1):1571–7. <https://doi.org/10.53359/mfi.v15i1.140>
63. Mostafavinia A, Amini A, Ghorishi SK, Pouriran R, Bayat M. The Effects Of Dosage and The Routes of Administrations Of Streptozotocin And Alloxan On Induction Rate of Type1 Diabetes Mellitus and Mortality Rate in Rats. *Lab Anim Res.* 2016;32(3):160. <https://doi.org/10.5625/lar.2016.32.3.160>
64. Schumann G, Bonora R, Ceriotti F, Féraud G, Ferrero CA, Franck PFH, et al. IFCC Primary Reference Procedures For The Measurement Of Catalytic Activity Concentrations Of Enzymes At 37 Degrees C. International Federation of Clinical Chemistry and Laboratory Medicine. Part 6. Reference Procedure for The Measurement of Catalytic Con. *Clin Chem Lab Med.* 2002;40(7):734–8. <https://doi.org/10.1515/cclm.2002.110>
65. Akrom, Akrom. (2015). Hepatoprotector Activity of Simvastatin in Rats Sprague Dawley Induced by Alloxan. *Media Farmasi. Media Farmasi Vol 12 No.1 Maret 2015: 104-119. 104-119.* https://www.researchgate.net/publication/297763520_HEPATOPROTECTO_R_ACTIVITY_OF_SIMVASTATIN_IN_RATS_Sprague_Dawley_INDUCED_BY_ALLOXAN
66. Wu, Z., Gong, H., Shen, Y. *et al.* Hypoglycemic and hypolipidemic effects of sugar beet (*Beta vulgaris* L.) extract on C57BL/KsJ db/db mice. *Rend. Fis. Acc. Lincei.* 2022 33, p. 205–212. <https://doi.org/10.1111/jcmm.13876>
67. Lukiswanto BS, Yuniarti WM. Altered Liver and Renal Serum Marker Enzymes in Alloxan Induced Diabetes Rats Treated with *Phyllanthus niruri* . *J of Applied Environmental and Biological Sciences.* 2016; 94-8. <http://repository.unair.ac.id/84742/1/06.%20Altered%20Liver%20and%20Renal%20Serum%20Marker%20....pdf>
68. Fan, W., Liu, A., Wang, W., Zheng, G., & Teng, A. Hepatoprotective activity of CrPic against alloxan-induced hepatotoxicity in mice. *Biological Trace Element Research.* 2012. 149(2), p. 227–233. <https://doi.org/10.1007/s12011-012-9415-8>
69. Costello RA, Nicolas S, Shivkumar A. Sulfonylureas. [Updated 2022 Aug 25]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan-. <https://www.ncbi.nlm.nih.gov/books/NBK513225/>
70. Takahashi Y, Sugimoto K, Inui H, Fukusato T. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.

World J Gastroenterol. 2015 Apr 7;21(13):3777-85.
<https://doi.org/10.3748/wjg.v21.i13.3777>

71. Mazzotti A, Caletti MT, Marchignoli F, Forlani G, Marchesini G. Which treatment for type 2 diabetes associated with non-alcoholic fatty liver disease? Dig Liver Dis. 2017 Mar;49(3):235-240.
<https://doi.org/10.1016/j.dld.2016.12.028>

